7 November 2024
Apex Molecular Ltd appoints Dr Jason Tierney as a Medicinal Chemistry Consultant
Apex Molecular Limited announces the appointment of Dr Jason Tierney as a medicinal chemistry consultant to work on their external customer medicinal chemistry drug discovery projects. Jason is an experienced Drug Hunter, having over 25 years’ experience in Drug Discovery, both...
15 October 2024
Monument Therapeutics secures £1m investment to fund its schizophrenia programme and drive next stage of growth
Manchester, UK, 15 October 2024 - Monument Therapeutics, a precision neuroscience company, today announced a further £1M equity investment by the Forster Foundation, a charitable incorporated organisation. The new investment builds on equity and non-dilutive funding announced in...
25 September 2024
LYVA Labs invests £50,000 into health innovators Tectores
YVA Labs has completed a £50,000 investment into Tectores Ltd, a Wirral-based healthcare company. Tectores’ patented anti-friction technology, PelliTec®, is currently available in a pad, which is worn inside footwear to prevent blisters. The pad has been shown to reduce the...
18 September 2024
Monument Therapeutics announces grant of UK patent for neuroinflammation compound MT1980
MANCHESTER, England, Sept. 17, 2024 - Monument Therapeutics, a stratified medicine company developing novel treatments for areas of high unmet need in psychiatry and neurology, today announced that the United Kingdom Intellectual Property Office ("IPO") has granted UK patent...
17 September 2024
First NCFB patient dosed in RESP-X Phase IIa study
Alderley Park, Cheshire, U.K. Infex Therapeutics, a leading anti-infectives specialist, announces that the first patient has been dosed in a Phase IIa clinical trial for RESP-X, a new anti-virulence therapy to treat Pseudomonas aeruginosa (Pa) infections in non-cystic fibrosis...
10 September 2024
QV Bioelectronics delivers breakthrough pre-clinical safety and efficacy results for Electric Field Therapy in the treatment of Glioblastoma
• Safety of QV’s novel stimulation regimes demonstrated in large animal studies for up to three months of implantation. • Pre-clinical data demonstrates QV’s breakthrough proprietary stimulation methodology outperforms that of the industry leader in its effectiveness against...
6 September 2024
Respected pharma data science pioneer Dr Ben Sidders to spearhead Biorelate's next growth phase as Chief Scientific Officer
Dr Sidders brings two decades of deep data science experience, honed across multiple therapeutic areas at Pfizer and AstraZeneca. He will build on Biorelate's strong track record of leveraging advanced data science methods to extract critical knowledge from vast amounts of...
5 September 2024
QV Bioelectronics secures £343,000 from Innovate UK’s Cancer Therapeutics programme to develop a new treatment for childhood brain tumours
• The project will adapt QV Bioelectronics’ existing electric field therapy (EFT) technology to develop the world’s first fully implantable EFT device to treat Diffuse Midline Glioma (DMG). • DMG is a highly aggressive childhood brain cancer and ultra-orphan disease with a...
3 September 2024
Infex Therapeutics to present RESP-X Phase I data at ERS Congress
Alderley Park, Cheshire, U.K. Infex Therapeutics, a leading anti-infectives specialist, announces that Phase I data from RESP-X, the Company’s first-in-class anti-virulence antibody, will be presented in an oral presentation by Colm Leonard, Chief Clinical Officer at Infex, at...
27 August 2024
Cessatech and Proveca announce world-wide excluding US commercial partnership for CT001
COPENHAGEN, Denmark, Aug. 26, 2024 /PRNewswire/ -- On 26 August – Cessatech A/S ("Cessatech" or "the Company") announces that the Company has entered into an exclusive commercialization agreement with Proveca Ltd - a global pharmaceutical company which specialises in the...